>MOOC attracts 270M users
我国约2.7亿人学习慕课
文章插图
A student from Shanghai Jiaotong University watches a video lecture from an online education platform called "Nanyang Academy" via his iPad. Provided to China Daily
About 270 million people have taken massive open online courses (MOOC) in China as of August this year, according to the Ministry of Education.
教育部称，截至今年8月，我国慕课学习人数约达2.7亿 。
With around 15,000 courses, China has built an extensive MOOC network offering a wide range of courses across a variety of disciplines, said the ministry. Of the users, about 80 million were college students, the ministry said.目前慕课数量约1.5万门，我国已建成涵盖多个学科、内容广泛的慕课网络 。教育部称，在慕课学习者中，约有8000万人为高校学生 。
The MOOC network has notably contributed to education equity. Under several programs sponsored by the ministry, colleges and universities in less-developed western regions have tried to introduce open online courses in their curriculums and trained their faculty in integrating online and offline courses. 慕课网络为教育公平作出了巨大的贡献 。在教育部组织的几项计划中，多所西部欠发达地区的高校试图在其课程中引入在线开放课程，并就整合线上线下课程对教职员工进行培训 。
As of now, they have introduced more than 8,000 courses online or online-offline and 52,000 teachers have received the training. The ministry also plans to launch a bilingual gateway website of China MOOC by the end of this year to connect about 20 Chinese MOOC websites.截至目前，西部高校引入线上教学或线上线下课程8000余门，接受培训教师达5.2万人次 。教育部还计划于今年年底前推出中国慕课双语门户网站，以连接国内约20个慕课网站 。
>New Alzheimer\'s drug accepted
国产新药治疗老年痴呆
文章插图
GV-971, the home-grown drug treating Alzheimer\'s disease. [Photo provided to chinadaily.com.cn]
A home-grown drug for treating Alzheimer\'s disease has been approved by the National Medical Products Administration to hit the market.
近日，国家药品监督管理局批准了一款治疗阿尔茨海默病(老年痴呆)的国产新药的上市申请 。
The new drug, GV-971, was developed by Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences and Green Valley Pharmaceutical Co Ltd, after research efforts of 22 years. It is the world\'s first innovative therapy for treating Alzheimer\'s disease in 17 years. 这款药名为"九期一"(甘露特钠，代号：GV-971)，由中国海洋大学、中国科学院上海药物研究所和绿谷制药有限公司历时22年研制，是17年来全球首个治疗阿尔茨海默病的创新性疗法 。
Alzheimer\'s disease is an irreversible and progressive brain disorder that slowly destroys memory, thinking ability and the capability to carry out simple tasks. China has roughly 10 million people with Alzheimer\'s, the most in the world. 阿尔茨海默病是一种不可逆的、渐进型大脑紊乱病症，会慢慢破坏人的记忆力、思考能力以及执行简单任务的能力 。我国约1000万人患有阿尔茨海默病，是全球患者人数最多的国家 。
The 36-week-long Phase 3 clinical study showed that the drug can improve cognition in patients with mild to moderate Alzheimer\'s disease, the developers said. The first production line for the drug will begin running this week. Patients will be able to buy the drug around the country from Dec 29, according to Shanghai Green Valley Pharmaceutical Co Ltd.该药研发机构称，为期36周的第三阶段临床研究显示，此药可改善轻度至中度阿尔茨海默病患者的认知能力 。上海绿谷制药有限公司表示，"九期一"将于本周投产第一批，预计12月29日投放至全国 。
特别声明：本站内容均来自网友提供或互联网，仅供参考，请勿用于商业和其他非法用途。如果侵犯了您的权益请与我们联系，我们将在24小时内删除。